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1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia. While many strides have
been made in elucidating the underlying causes of AD, studying the disorder in vivo has
faced several hurdles: First, the structures affected by AD lie deep within the brain where
biopsy is not practical. Second, animal models do not develop AD naturally, and genetically
engineered models designed to mimic AD do not fully reproduce the human phenotypes
[1-3]. Third, while studies using Positron Emission Tomography (PET) have been very use‐
ful for examining plaques and metabolic changes, they involve the injection of radioactive
contrast agents. Many of these materials have short half-lives and must be created on-site,
making PET very expensive and difficult to be performed at non-specialized centers. Finally,
studies which examine cerebrospinal fluid (CSF) require participants to undergo an invasive
and sometimes painful lumbar puncture, potentially on multiple occasions [4-7]
In contrast to other techniques, Magnetic Resonance (MR) offers a non-invasive method for
analyzing structural and functional brain characteristics without the need for ionizing radia‐
tion. In other words, it can be performed in longitudinal studies without significant health
concerns. Multiple scans can be performed quickly in the same testing session to assess tis‐
sue response to tasks or pharmacological administration. The scans are generally 2-5 mi‐
nutes each and many analyses can be done post-hoc. Conveniently, most hospitals and
clinics already possess the MR scanners at field strengths of 1.5 and 3.0 Tesla (T).
Many MR techniques have been used to understand the underlying pathology in patient
populations  already  diagnosed  with  AD.  Because  MR  studies  require  absolute  stillness
for several  minutes,  and some functional  scans require the patient to focus on perform‐
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ing a difficult task, performing MR work in advanced AD cases is quite challenging and
as  such,  most  studies  are  limited to  mild  and very  mild  cases.  While  these  studies  are
typically  performed  at  a  time  when  pathology  is  irreversible,  the  results  of  this  work
point to changes that may be apparent before cognitive decline has become clinically ap‐
parent.  For this reason, studies that examine differences between people who will  even‐
tually  develop AD and people  who will  not  develop AD provide insight  into  both the
cause and the physiology of the disease.
It is impossible to predict with certainty who will develop AD, but there are several fac‐
tors that increase the risk. These at-risk populations include individuals in the prodromal
stage of AD, termed amnestic mild cognitive impairment (aMCI), and people at a genetic
risk  for  developing AD.  A diagnosis  of  aMCI indicates  that  there  is  more  memory de‐
cline  than  would  be  expected  based  on  the  person’s  age  and education  level,  however
memory impairment is not interfering with daily activities. It is estimated that 10-20% of
people 65 and older have aMCI, and out of those 10-15% will progress to develop AD in
3-4 years.  [8,9]  Because approximately 30% of people diagnosed with aMCI will  remain
stable  or  improve over  time,  it  is  important  to  find biomarkers  that  will  identify  those
most likely to progress to AD.
This chapter will focus on the use of MR in the early detection of AD. Major advances have
been made in structural imaging of both gray and white matter using proton density, T1-
and T2- weighted imaging, and Diffusion Tensor Imaging (DTI). Functional imaging in AD
will also be reviewed, and Blood Oxygenation Level-Dependent (BOLD) functional Magnet‐
ic Resonance Imaging (fMRI) will be broken down into its primary contributors: Cerebral
Blood Flow (CBF), Cerebral Blood Volume (CBV), and the Cerebral Metabolic Rate of Oxy‐
gen (CMRO2). Finally, hemodynamic fMRI contrast can be complemented using measures of
neurochemistry, including measuring the balance between excitatory (glutamatergic) and
inhibitory (γ-aminobutyric acid; GABAergic) neurotransmission. This can be achieved with
new single-voxel chemical imaging techniques such as Magnetic Resonance Spectroscopy
(MRS), or more recently using multi-voxel MRS imaging (MRSi)
2. Basics of MRI
Before reviewing the work that has been done with MR, a brief overview of the theory be‐
hind MR should be covered. MR physics can essentially be understood using principles of
classical physics, however for a more comprehensive understanding the reader is directed to
an excellent review by Plewes and Kucharzck [4,10]. Briefly, MR takes advantage of the be‐
havior of a system of protons in the presence of a magnetic field and how this behavior
changes based on the micro- and macroscopic environment. Magnetic strength is generally
reported in units of Tesla (T), and MRI scanners have very high field strengths. In human
research, 1.5T, 3T, and 7T scanners are commonly used, though 1.5T and 3T scanners pre‐
dominate the clinical setting. The magnet’s strength and direction is represented by the vec‐
tor B0 (see Figure 1), and lies along the Z-axis (generally from foot to head).
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Due to the large amount of water that constitutes tissue (~80-99% depending on tissue type),
most MR is specifically focused on the protons on water molecules. Protons have an intrinsic
spin that in nature is oriented randomly. In the presence of a magnetic field however, these
spins align themselves on average parallel or antiparallel to the axis of the field (Figure 1a).
The number of protons aligned parallel to the field is very slightly larger than the number of
protons aligned antiparallel, and it is this difference that produces the net magnetization
vector in a voxel. When a radiofrequency (RF) pulse is applied at the proper frequency (Lar‐
mor frequency), the longitudinal (z) component of the magnetization vector is tipped away
from the axis of the main magnetic field, but continues to spin around the longitudinal axis
or “precess” (Figure 1b). When the pulse is removed, the longitudinal component of the
magnetization vector will realign itself with the field with a unique time constant that varies
with the local environment.
Manipulating the timing of the RF pulses controls the magnetization and creates the desired
contrast. The most fundamental timing parameters of relevance are repetition time (TR),
echo time (TE), and in some cases inversion time (TI). TR is the time between consecutive
acquisitions, and TE is the time from the onset of the excitation pulse that is used for prepar‐
ing the signal for detection to the signal refocusing and in most cases acquisition. In an in‐
version recovery pulse sequence, TI refers to the time between the inversion pulse and the
excitation pulse. Importantly, simply by manipulating the timing of the above parameters a
range of MR contrasts can be obtained with varying sensitivity to different tissue types. A
simple pulse sequence indicating RF and gradient timing is illustrated in Figure 1c.
ܵ ∝ ܥ ∙ ܯ௓ ∙ ܯ௑௒
Figure 1. Physics underlying magnetic resonance. Hydrogen atoms align parallel and antiparallel to a strong magnetic
field, producing a net magnification vector (a). When a radio frequency pulse is applied at the Larmor frequency, the
net magnetization vector is tipped away from the main magnetic field (b). Example of a simple pulse sequence show‐
ing timing parameters of the application of radio frequency pulse (RF), the onset of gradients in the Z direction (Gz),
and the timing of signal acquisition (Signal) (c).
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In most cases, the detectible signal (S) that is measured in MRI is a combination of three pri‐
mary factors: water proton density (C; ml tissue /100 ml water ), magnetization in the longi‐
tudinal plane (MZ) and magnetization in the transverse plane (MXY):
S∝C ∙MZ ∙M XY (1)
The two major methods or “weighting” that are used for generating contrast are T1 and T2.
T1 and T2 are independent measures and reflect different properties of the tissue of interest,
with T1 governing the Mz term and T2 the Mxy term in Eq. 1 above. The time it takes for the
magnetization to realign itself longitudinally is measured using T1 weighting (Figure 2a),
and is achieved with a short TR and a short TE sequence. T1 is a constant that is unique for
each tissue type and is equal to the point when 63% of longitudinal magnetization is recov‐
ered (Figure 2b). At the times selected for T1 imaging, there is a high amount of contrast be‐
tween gray and white matter and therefore T1 weighted imaging is useful for viewing
structural changes in the brain (Figure 2c).
 
ܯ௓ ൌ ሺ1 െ ߙ݁ష೅಺೅భ ൅ ݁ష೅ೃ೅భ ሻ

ܯ௑௒ ൌ ݁ି்ா/்ଶ
Figure 2. T1 weighted imaging. After removal of an RF pulse the magnetization vector recovers longitudinally (a). The
recovery time is a constant for each tissue type based on the magnetic field strength that is applied (b). Example T1
weighted images (c).
The MZ component of the magnetization vector is based on pulse timing as well as the T1 of
tissue, and for magnetization following a pre-pulse with flip angle, α, is given by:
MZ = (1 - αe -TIT 1 + e -TRT 1 ) (2)
Understanding Alzheimer's Disease228
Note that in the absence of a prepulse (α=0), the TR determines the T1-weighting. When the
RF pulse is applied, individual protons will also precess in synchrony in the transverse
plane. When the pulse is removed, the protons will lose that synchrony or dephase, which
results in a reduced MXY (Figure 3a). This is referred to as T2 decay. Like T1, the T2 time
constant is unique for each tissue (Figure 3b). Unlike T1, T2 weighting is achieved with a
long TE and long TR.




Figure 3. T2 weighted imaging. Protons lose synchrony after removal of an RF pulse (a). The amount of time it takes
for protons to lose synchrony is a constant that is unique to each tissue type (b). Example of T2 weighted images (c).
The MXY component of MRI is based on pulse timing as well as the T2 constant of the tissue
area, and can be written:
M XY = e -TE /T 2 (3)
The three equations can be combined to form one overall equation for the MR signal that
takes into account both the T1 and the T2 properties of the tissue:
S∝C ∙ (1 - αe -TIT 1 + e -TRT 1 )∙ e -TE /T 2 (4)
T1 and T2 components are each present whenever a proton is flipped out of alignment, but
by manipulating the pulse sequences one can contribute to the signal more than the other.
This is referred to as weighting. If neither the T1 nor the T2 signal contributes strongly to the
signal, only the C component is left. These images are referred to as proton density images.




By far, the most established use of MR is to examine the gross anatomy of the brain. With
the right specifications, MR can provide a highly detailed three-dimensional image that al‐
lows for the examination of brain structures. Weighting is used to provide contrast for the
tissue of interest.
3.1. Anatomical imaging
T1 weighted imaging is used to visualize structural changes in tissue. At a field strength of 3
Tesla, T1 weighted images can be acquired in about five minutes and have a resolution of
approximately 1 mm3.
The most significant differences reported in patients are atrophy of the structures in the
medial  temporal  lobe  (MTL)  which  typically  follow the  “Braak  stages”  of  AD progres‐
sion [11].  Briefly,  pathology starts  in the transentorhinal  region (stages I  and II),  moves
to the limbic region (stages III and IV) and ends in isocortical regions (stages V and VI).
Studies that have been done in AD patients show that hippocampal and entorhinal cor‐
tex volume change, as well as temporal lobe morphology changes are the best measures
to predict change over time [12].  A higher level of regional brain atrophy has also been
associated with decreased levels of Aβ-42 and increased levels of phosphorylated tau in
the CSF of AD patients [12].
In patients who have been diagnosed with aMCI, changes to the parahippocampal region
are already apparent. It is up for debate whether the investigation of the entire brain or just
volumes of interest (VOIs) are better at predicting conversion from aMCI to AD, but in a re‐
cent meta-analysis of work using data from the Alzheimer’s Disease Neuroimaging Initia‐
tive (ADNI) only four methods were able to distinguish those who would convert more
accurately than random chance. None of the four were more statistically reliable than the
others, but three examined VOIs (Voxel-STAND, 57% sensitivity and 78% specificity; Voxel-
COMPARE, 62% sensitivity and 67% specificity; Hippo-Volume, 62% sensitivity and 69%
specificity) while only one examined the entire brain (Thickness-Direct, 32% sensitivity and
91% specificity) [11,13-15]. A protocol devised by Chincarini et al. to sample several VOIs
has demonstrated a method of separating converters from non-converters with a sensitivity
of 71% and a specificity of 65% [16,17]. Another method for predicting conversion is examin‐
ing hippocampal shape, and Costafreda et. al. were able to develop a method with 77% sen‐
sitivity and 80% specificity. [18,19].
Patients that are at-risk for AD but have no cognitive deficit are much more difficult to iden‐
tify. Most studies have been done in carriers of the ApoE ε4 allele, however it is important to
remember that these studies have been cross sectional, and therefore may reflect a conse‐
quence of the gene that makes carriers more susceptible to AD, but not necessarily a stage of
AD itself. There have been cortical thinning signatures identified in children, adolescent,
and young adult carriers of the ε4 allele. These signatures reflect reductions in dorsolateral
and medial prefrontal, lateral, temporal, and parietal cortices. [20-22]. Middle-aged carriers
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of the ε4 allele were found to have a thinning of the cortex in the entorhinal region, subicu‐
lum, and other MTL structures, although the results were stronger in those with a family
history of AD than those that carried the ε4 allele alone [23,24].
The detectible changes are not limited to atrophy. There have been several studies that have
discovered an increase in gray matter in young adult carriers of the ε4 ellele. Increases were
found in bilateral cerebellar, occipital, and thalamic regions as well as in the fusiform and
right lingual gyri [22,25]. Recent work has also suggested that changes in the basal choliner‐
gic forebrain may be detectible decades before cognitive impairment, although this study
did not take into account genetic status [26].
One of the significant weaknesses of analyzing structural changes is that the regions of inter‐
est can vary in size even across healthy individuals. Longitudinal studies are the only way
to control for this variability. Secondly, the atrophy of brain regions likely occurs secondary
to functional changes. The assessment of atrophy alone gives little information as to the un‐
derlying factors that led to neuronal loss.
3.2. White matter imaging
Unlike T1 weighted imaging, T2 imaging relies on the dephasing of the magnetization vec‐
tor in the transverse plane. T2 weighting, specifically FLuid Attenuated Inversion Recovery
(FLAIR) imaging, is used to identify White Matter Hyperintensities (WMH), which are in‐
creased in AD [27]. In contrast, diffusion tensor imaging (DTI) is able to indirectly measure
the integrity of myelin sheaths surrounding white matter tracts, and Susceptibility weighted
imaging (SWI) is able to distinguish tissues at a high resolution based on several properties.
FLuid Attenuated Inversion Recovery (FLAIR) and Diffusion Tensor Imaging (DTI)
If simply T2 weighted imaging was used, the signal from Cerebrospinal Fluid (CSF) is
strong and therefore very bright (T2 of CSF ~ 600 ms at 3T). This makes it difficult to see
subtle abnormalities in the white matter regions that partial volume with CSF. FLAIR imag‐
ing nulls the signal from CSF so that the image is focused solely on the white matter. The
first RF pulse inverts the magnetization by 180 degrees. Then, when the longitudinal mag‐
netization for the CSF = 0, an excitation pulse and readout is applied. Because T1 of CSF
(~4000 ms at 3T) is much longer than that of tissue (T1~700-1200 ms at 3T), residual tissue
signal remains at the time of the CSF nulling.
DTI measures fractional anisotropy (FA), a quantitative measure of the coordinated move‐
ment of water molecules. FA assumes that the stronger a white matter tract is, the more like‐
ly the water molecules will be to move along the tract rather than sideways within the
myelin sheath. If the myelin sheath is damaged it becomes easier for water molecules to dif‐
fuse through it, and the FA value will decrease.
The loss of white matter integrity, either through WMH or FA differences, may correlate
with increasing cognitive impairment [28,29]. In AD populations reduced FA values have
been found in frontal and temporal lobes, the posterior cingulum, the corpus callosum, the
superior longitudinal fasciculus and the uncinate fasciculus [30]. Both WMH and FA have
been found to distinguish normal aging from aMCI[31] and predict conversion from aMCI
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to AD[32]. Results have differed in whether they correlate with ApoE ε4 status, with some
studies saying they do not [33,34], while several others say they do [35-37]. Note that the
studies that claim white matter integrity correlates with ApoE ε4 status are more recent, and
their ability to detect differences are likely more sensitive. White matter integrity has also
been found to correlate with a family history of AD regardless of ApoE status [38,39].
White matter hyperintensities are associated with vascular abnormalities and therefore
highly correlated with cardiovascular disease. For this reason, many clinicians will exclude a
diagnosis of AD if there are many apparent WMH and instead diagnose the patient with
vascular dementia [32]. Many non-amnestic MCI patients tend to have a higher degree of
cardiovascular disease than those with aMCI or AD, however aMCI and AD patients have
increased WMH scores. For this reason, increased WMH scores in cognitively impaired indi‐
viduals is likely associated with neurological disease rather than vascular disease [32].
Susceptibility Weighted Imaging (SWI)
Susceptibility weighted imaging is  a method that can discriminate tissue content with a
high level of resolution based on the tissue’s intrinsic magnetic properties. SWI uses T2*
weighting along with magnitude and phase information to  enhance contrast,  and when
combined  with  traditional  MR  weighting  it  can  be  used  to  detect  small  differences  in
susceptibility between blood and tissue. It is particularly useful for detecting cerebral mi‐
crobleeds because it  can exploit the magnetic properties of blood since the susceptibility
effects  from fully  oxygenated (arterial)  and partially  de-oxygenated (venous)  blood wa‐
ter,  and tissue,  varies  greatly  –  especially  at  high field  strength.  It  can  also  be  used to
measure the iron content of a tissue.
Microbleeds are inversely correlated with performance during cognitive testing in healthy
older adults, although this finding has never reached significance in an AD population
[13,14]. SWI would allow for improved visualization of microbleeds so that if there is a rela‐
tionship between microbleeds and susceptibility to AD pathology, it can be recognized.
Techniques are being developed that semi-automatically detect cerebral microbleeds with
little human interference. These would significantly reduce the processing time and stand‐
ardize the quantification of microbleeds across patients and imaging centers.
In addition to microbleeds, one marker of oxidative stress is an increase in a tissue’s iron
content.  Iron levels are highly elevated in AD patients as well  as those with aMCI, and
it  is  thought that changes in iron content may be detectible decades before the onset of
the disease [16]. There is a theory that Aβ deposition may occur as a cellular response to
an  increased level  of  iron,  and this  is  one  of  the  underlying  causes  of  amyloid  plaque
formation[40].  SWI has  been shown to  be  a  promising method to  non-invasively  assess
iron distribution, and determine if there is a link between iron accumulation and the on‐
set of AD pathology [18].
SWI has only been used as a technique since 2004, which makes it very new technology. Al‐
though it has not yet been used in an at-risk population, SWI studies will likely be important
tools in assessing AD risk.
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3.3. Future of structural imaging
There is still a lot of work to be done in structural imaging. Most clinical studies to date have
used 1.5 Tesla (T) scanners, however many medical centers now have 3T scanners and there
are approximately 50 7T scanners worldwide. These high-field scanners allow for increased
resolution, and provide better spatial resolution for observing structural changes in the
same scan time. Although 7T scanners are not yet FDA approved for clinical use, they are
already being utilized in neuroimaging research, including in patients with AD.
Many atrophy measurements are made either through a trained radiologist’s visual assess‐
ment, or by manually tracing the area of interest. As such, the measurement of atrophy can
be subjective, and is not always reproducible across testing site. In fact, one study found that
the ability of radiologists to diagnose subjects based on atrophy alone had a specificity of
85% and a sensitivity of only 27% [20]. The introduction of FDA-approved methods that can
automatically detect atrophy will create standardization of the field, and decrease variability
across medical centers [41].
4. Functional imaging
While structural imaging is important to assess brain atrophy, the hope is that AD patholo‐
gy will be identified before neuronal death so that atrophy can be prevented. One current
theory is that one of the major components leading to amyloid and tau pathologies could be
vascular changes [42]. Two of the risk factors for AD are mutated forms of APP, and the
ApoE ε4 isoform and both of these factors are involved in cholesterol processing. The inabil‐
ity of a neuron to clear amyloid plaques may be prognostic and indicate impaired blood
flow as a risk factor for AD. While it is not immediately apparent how blood flow is contri‐
buting to AD, some vascular changes are being evaluated through the use of hemodynamic-
based functional imaging techniques.
4.1. BOLD fMRI
Functional magnetic resonance imaging, or fMRI is a way to gain insight into the functional
processes occurring in the brain. Most fMRI modalities are based on the blood oxygenation
level-dependent (BOLD) effect. This is an indirect method of tracking the activation or inac‐
tivation of brain regions relative to a baseline state, and is based on the idea that an active
area will need more energy and consume more glucose and oxygen and therefore more
blood will need to be directed to that area. More specifically, oxygenated and deoxygenated
blood water have different intrinsic magnetic properties (oxygenated blood is diamagnetic
and deoxygenated blood is paramagnetic) and therefore affect the T2 and T2* relaxation
times of surrounding water in blood and tissue in different ways. Deoxygenated blood has a
strong enough magnetic affect (paramagnetic) that it will distort the local field and decrease
the signal intensity (i.e. shorten T2) of surrounding water for that region. Oxygenated blood
will not have the same effect, and therefore regions containing more oxygenated blood will
have higher signal intensity (longer T2). Importantly, during functional activation the cere‐
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bral blood flow increases by a large amount (20-100%) relative to the cerebral metabolic rate
of oxygen consumption (CMRO2), resulting in a relative decrease in the concentration of de‐
oxyhemoglobin in capillaries and veins. By comparing the signal intensities of regions at
baseline (Figure 4a) and during a task (Figure 4b), the regions that have an increase in capil‐
lary and venous oxygenation can be visualized.
 
Figure 4. Blood flow at rest (a) and during activation (b)
BOLD imaging involves very fast sequences in order to visualize changes in functional acti‐
vation on the timescale of the hemodynamic response. This rapid sequencing allows for a
time resolution of approximately 2s. Total time required to perform a BOLD scan varies
with the task being performed, but typically scans take 5-15 minutes.
There are two main types of fMRI: evoked (task-related) and spontaneous (“resting” state).
Evoked fMRI is the more commonly performed test in which the same task is repeated
many times with a baseline measurement taken between trials. Statistical tests (Z- and t-
tests) are used to differentiate the regions activated during the task from those active at
baseline. By contrast, spontaneous BOLD specifically measures synchrony of baseline signal
fluctuations to determine how the brain is functionally connected.
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Evoked BOLD fMRI
There are several established testing paradigms that have been designed to study memo‐
ry.  The most  commonly used paradigms look specifically at  either  episodic or  semantic
memory. Episodic memories involve the recognition of autobiographical or cued informa‐
tion (e.g.,  faces, words, other visual stimuli) while semantic memory involves the recog‐
nition  of  a  fact  or  information  regardless  of  personal  context  (e.g.,  famous  faces,
geographical  locations).  Because episodic memory is  highly affected by AD, many fMRI
paradigms use an episodic memory task to elicit  functional differences between patients
and controls.  While  encoding  a  new memory,  activation  of  the  hippocampal  and para‐
hippocampal regions is decreased in mild AD patients compared to healthy controls [43].
In  a  block  design  face  name paradigm,  AD patients  also  show decreased  hippocampal
activation to novel stimuli compared to repeated comparisons [43].
A multitude of studies have been performed in asymptomatic carriers of ApoE ε4 with
mixed results. In an extensive review of the literature by Trachtenberg et al, some claim that
carriers have increased activation across brain structures while others claim the oppo‐
site[44]. Moreover, there have been reports of both increases and decreases of activation or
that there is no significant effect at all of carrying the ApoE ε4 allele[44]. In each case, inves‐
tigators have provided hypotheses to explain both increased and decreased activation in
ApoE ε4 carriers: decreased activation can be easily explained by the fact that presympto‐
matic carriers are already accumulating AD pathology hallmarks before cognitive decline is
experienced. These pathologies may be hindering the BOLD response in the specific areas
that experience a decrease in activation, or they may be inhibiting areas that lie functionally
upstream. In contrast, an increase in activation can be explained in two ways, which take
into account AD pathology. For one, the accumulation of pathology may lead to the dedif‐
ferentiation of neural network such that many networks become involved in a specific proc‐
ess. This may in fact be a part of healthy aging [45] and could be found in young,
presymptomatic carriers of ApoE ε4 because their brains are aging more rapidly. Alterna‐
tively, the brain may have a cognitive reserve that needs to “work harder” during a difficult
task to perform at a normal level, and thus would have a higher amount of activation.
Trachtenberg et al [44] argue that the populations tested in these studies are very young (20s
and 30s) and have a great deal of time before they will begin to experience cognitive decline.
He suggests instead that the possession of an ApoE ε4 allele leads to a fundamental differ‐
ence in neurophysiology that could be contributing to this effect.
A growing body of evidence suggests that an episodic memory task may not be the best way
to characterize memory loss because episodic memory declines as a part of healthy aging as
well. Episodic memory tasks are also more difficult than semantic memory tasks, The work
may therefore be experiencing a basement effect[45]. Semantic memory, in contrast, is affect‐
ed very early in AD, but remains relatively untouched in the healthy aging process [45].
Most semantic memory tests involve the recognition of famous names and faces [45-47] or
categorizing word lists [1,3]. These types of studies have shown an increase in activation
and a decrease in deactivation the MTL regions of carriers of the ApoE ε4 allele.
Spontaneous BOLD fMRI
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Resting state, or functional connectivity MRI (fcMRI) is a task-independent measurement of
brain regions that fluctuate in their BOLD signal together, indicating that they are function‐
ally connected. The Default Mode Network (DMN) is a collection of brain regions that seem
to activate together while the brain is at rest, and are deactivated while the brain is engaged
in a cognitive task. The DMN is composed of MTL and lateral frontal regions, particularly
the posterior cingulate complex [4,6,7]. This network is altered in AD and is a potent bio‐
marker for separating patients with AD from healthy controls [8], patients with aMCI from
healthy controls [48], and genetically at-risk individuals from healthy controls [4].
Caveats to BOLD fMRI
Although BOLD fMRI is an important tool for research, there are some limitations to its clin‐
ical feasibility as a biomarker for future AD. To date, it has not successfully been used in
predicting patient prognosis or trajectory. In terms of practicality, fMRI is expensive and re‐
quires extensive image processing, which will drive up the cost of any tests. It is also not
completely reproducible across testing sites or days. Different equipment and software can
create variables in data analysis across testing sites. Longitudinal studies can present diffi‐
culties because as they age, patients may develop comorbidities, or begin taking drugs that
will interfere with the BOLD signal in a way unrelated to AD pathology. Even subtle
changes can influence the BOLD signal such as recent alcohol [49] or caffeine [50] intake.
The biggest difficulty with BOLD fMRI is that it is generally not quantitative. Changes in
blood oxygenation are based on three individual components: Cerebral Blood Flow (CBF),
Cerebral Blood Volume (CBV), and the Cerebral Metabolic Rate of Oxygen (CMRO2) [51].
Figure 5 represents the many ways that CBF, CBV, and CMRO2 can contribute to the BOLD
effect. It is impossible to determine which of these is contributing to a BOLD fluctuation
with fMRI alone. For this reason, vascular imaging techniques are being developed that are
able to quantitatively determine the physiological changes that are contributing to the BOLD
signal. Techniques to quantify CBF and CBV have been validated and are gaining populari‐
ty. CMRO2 methods are still in development and have not been used in an AD population
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Figure 5. Positive and negative BOLD effects are influenced by CBF, CBV, and CMRO2 and it is not possible to distin‐
guish which factor is contributing by only measuring BOLD.
4.2. Cerebral blood flow
Cerebral blood flow is a measurement of the rate of tissue perfusion, usually measured by
the amount of blood that reaches a tissue per unit time (mL blood per 100 g tissue per mi‐
nute) [52]. CBF has been quantified by Positron Emission Tomography (PET) [53,54] and
Single Photon Emission Computed Tomography (SPECT) [10,55,56] but today it can also be
quantified noninvasively using a technique called Arterial Spin Labeling (ASL). ASL uses a
radiofrequency pulse to label blood water in an area outside of the region of interest, usually
in the neck. After 1-2s, the labeled blood water flows into the imaging region and exchanges
with tissue water and a tagged image can be obtained [51,57]. This image is compared with
an image where the blood water is not labeled, and the difference between the two images
provides a map proportional to CBF. As can be seen, ASL is analogous to tracer-based ap‐
proaches such as 15O PET and Gadolinium-MRI, however the tracer is endogenous blood
water as opposed to an exogenous contrast agents. Whole-brain ASL scans can be per‐
formed in less than 5 minutes with a spatial resolution of 3-5 mm.
In AD patients, deficits in CBF have been seen in the temporoparietal cortex, posterior cin‐
gulate cortex, and frontal cortex [57-59]. CBF as measured by ASL has been shown to be in‐
creased in aMCI patients but decreased pre-symptomatic carriers of ApoE ε4 [11,60]. The
increase that is seen in aMCI has been attributed to compensatory mechanisms [60].
Often, changes in blood flow precede structural changes, but reduced CBF is not necessarily
an indicator of vascular dysfunction. For instance, CBF alterations may be due to a lower
metabolic demand, cardiac output, or blood pressure [10,61,62]. Longitudinal analysis of
CBF in at-risk populations should be developed for its potential as a method for tracking
disease progress or recognizing it before cognitive symptoms begin.
4.3. Cerebral blood volume
Cerebral blood volume measures the amount of blood per 100 mL brain tissue. It is an indi‐
rect measurement of the vascularization of brain regions, and is less dependent on the sub‐
ject’s respiration than CBF[11,15,63,64]. There are currently two major techniques that
measure CBV: Dynamic Susceptibility Contrast MRI (DSC-MRI) and Vascular Space Occu‐
pancy MRI (VASO). DSC-MRI involves the injection of gadolinium as a contrast agent, and
is the best validated measure. Unfortunately, the injection of gadolinium is dose-restricted
because of its toxic effect on kidneys which limits its potential for longitudinal studies and
older patient populations [17,65]. VASO is a completely non-invasive method of measuring
CBV changes and has been gaining popularity in recent years. Unlike DSC-MRI, VASO uses
endogenous blood water as a contrast agent. VASO can be performed by measuring the tis‐
sue signal with and without blood water nulled, and subtracting one image from the other.
Although VASO is correlated with DSC-MRI there are some minor variations in the two
measurements, suggesting that the underlying physiology may be different [19,63].
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VASO has been applied to a mixed group of patients with aMCI and AD and found that
there are CBV reductions in the frontal and parietal lobes. These reductions were most strik‐
ing in white matter which suggests that any vascular component of AD is especially damag‐
ing to white matter compared to gray matter [21,22,61]. In the future, longitudinal studies
should be performed in carriers of ApoE ε4 to determine if these white matter vascular defi‐
ciencies can be recognized at a young age.
5. Chemical imaging
Structural and functional imaging are important for assessing the damage caused by AD,
but for designing therapeutics the ability to view changes at the macromolecular level
would be highly beneficial. New techniques are being developed that can do just that. Mag‐
netic Resonance Spectroscopy (MRS) can be done in a single voxel or across multiple voxels
(MRS imaging, MRSi) to assess macromolecular concentration. Both are new techniques that
are still being optimized, but will be extremely useful in understanding AD.
5.1. Magnetic resonance spectroscopy
MR imaging primarily measures signal from water protons, but in MR spectroscopy protons
of various metabolites can be assessed at one time. Quantification is achieved by exciting a
single voxel with a combination of RF pulses, and obtaining a free induction decay (FID)
spectrum. When this spectrum is Fourier transformed, metabolites can be visualized due to
their variability in chemical shift (Figure 6). Because the chemical shift of a single metabolite
is constant, it will always peak at the same frequency (measured in parts per million, ppm).
By calculating the area under the peak, the concentration of a metabolite relative to an inter‐
nal standard can be obtained.
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Figure 6. Example of chemical shift spectrum from a normal brain (from the University of Missouri-Kansas City Radiol‐
ogy Resident Resource Webpage
The  most  common macromolecules  studied  in  neuroimaging  are  creatine  (Cr)  which  is
usually  unaffected  by  disease  and  can  act  as  an  internal  standard,  N-acetyl-aspartate
(NAA), a marker for neuronal health,  myo-inositol (mI),  a marker of gliosis [32,66],  and
choline (Cho). In AD, NAA is typically decreased in AD and mI is typically increased so
NAA/Cr,  mI/Cr  and  NAA/mI  ratios  are  good  markers  of  the  disease  with  the  ratio  of
NAA to mI being the strongest.  The mI concentration has been found to be elevated in
aMCI [33,34,67].  There is  a trend that NAA is decreased in aMCI, however the effect  is
much more mild if  it  exists  [35-37,68].  Glutamate (Glu) is  the primary excitatory neuro‐
transmitter,  and is  significantly reduced in AD [69] Gamma-amino butyric  acid (GABA)
is an inhibitory neurotransmitter,  and its  concentration may be decreased in AD [70].  It
is possible to use MRS to estimate relative concentrations of both Glu and GABA in vivo,
but  due  to  their  low  concentrations  compared  to  NAA  and  other  metabolites,  and  the
fact that signal from these metabolites is very close in frequency space to other metabo‐
lites of  larger concentration,  it  is  more difficult  to identify them without suppressing or
“editing” other signals. One of the common methods used to quantify GABA is a PRESS
or  MEGA-PRESS  sequence  which  suppresses  or  edits  signals  from water,  creatine,  and
other  nearby  metabolites  so  that  the  characteristic  GABA  peaks  can  be  identified.  For
more information on the MEGA-PRESS sequence, see Waddell 2007 [71].
The importance of MRS research is clear,  but there are some difficulties associated with
it.  To  begin  with,  the  scans  take  a  long  time  to  complete—more  than  ten  minutes  in
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some cases—and because the measurements are taken in a single voxel the subject must
stay absolutely still throughout the scan. This is very difficult for young healthy subjects,
and may be nearly impossible in older, demented subjects. Common sedation drugs such
as  propofol  will  change  the  levels  of  brain  metabolites  and  should  be  avoided[72].  In
premenopausal women GABA levels also vary depending on the stage of the menstrual
cycle, and may introduce variability[73].
Typically, spectroscopy is done in the posterior cingulate or medial temporal cortices, but
these are only affected by AD in late stages of the disease. It would be more helpful to study
the smaller limbic areas that are affected sooner, but the voxel sizes typically used in spec‐
troscopy are larger than many of these areas [66]. Falini et al developed a technique to per‐
form spectroscopy across the entire brain and found that NAA levels are reduced in those
with AD, however whole-brain spectroscopy is a non-specific marker [41,74]. These limita‐
tions will be overcome with higher field strength, advances in shimming algorithms, and
improvements to computerized registration techniques [42,68].
5.2. Magnetic Resonance Spectroscopy imaging (MRSi)
MRSi is a technique that uses spectroscopy but applies it to voxels across the entire brain.
The concentration of the chemical of interest corresponds to the brightness or color of the
voxel in the image produced. It can achieve high spatial resolution (up to 0.25 cm3), and
when optimized can produce a wealth of information [44,75]. This technique has largely
been developed for breast cancer imaging, and can identify chemical “hot spots” that are of
use when categorizing a tumor. It has great potential as a technique for understanding AD.
6. Concluding remarks
There is still a long way to go before AD can be fully understood and treated. With magnetic
resonance technologies, it is possible to observe changes before cognitive decline begins. A
lot of work has been done with structural imaging of gray and white matter, and changes
are detectible in ApoE ε4 carriers decades before the onset of symptoms. More longitudinal
studies need to be performed to determine which of these changes will specifically lead to
AD. Functional studies offer a window of the changes that occur before neuronal atrophy,
but the specific vascular causes behind the BOLD effect need to be further studied. Finally,
chemical imaging can provide a glimpse of the changes occurring at the molecular level, and
by further developing and standardizing these measures there is much that can be learned.
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